Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12

1.

Draft Genomic Sequences of Nine Extraintestinal Pathogenic Escherichia coli Isolates from Retail Chicken Skin.

Xu A, Tilman S, Wisser-Parker K, Scullen OJ, Sommers CH.

Microbiol Resour Announc. 2018 Aug 23;7(7). pii: e00859-18. doi: 10.1128/MRA.00859-18. eCollection 2018 Aug.

2.

Combined administration of MF59-adjuvanted A/H5N1 prepandemic and seasonal influenza vaccines: long-term antibody persistence and robust booster responses 1 year after a one-dose priming schedule.

Lopez P, Caicedo Y, Sierra A, Tilman S, Clemens R, Banzhoff A.

Clin Vaccine Immunol. 2013 May;20(5):753-8. doi: 10.1128/CVI.00626-12. Epub 2013 Mar 27.

3.

Combined, concurrent, and sequential administration of seasonal influenza and MF59-adjuvanted A/H5N1 vaccines: a phase II randomized, controlled trial of immunogenicity and safety in healthy adults.

Lopez P, Caicedo Y, Sierra A, Tilman S, Banzhoff A, Clemens R.

J Infect Dis. 2011 Jun 15;203(12):1719-28. doi: 10.1093/infdis/jir191.

PMID:
21606530
4.

Immunogenicity and safety of MF59-adjuvanted H5N1 influenza vaccine from infancy to adolescence.

Vesikari T, Karvonen A, Tilman S, Borkowski A, Montomoli E, Banzhoff A, Clemens R.

Pediatrics. 2010 Oct;126(4):e762-70. doi: 10.1542/peds.2009-2628. Epub 2010 Sep 6.

PMID:
20819892
5.

MF59-adjuvanted H5N1 vaccine induces immunologic memory and heterotypic antibody responses in non-elderly and elderly adults.

Banzhoff A, Gasparini R, Laghi-Pasini F, Staniscia T, Durando P, Montomoli E, Capecchi PL, di Giovanni P, Sticchi L, Gentile C, Hilbert A, Brauer V, Tilman S, Podda A.

PLoS One. 2009;4(2):e4384. doi: 10.1371/journal.pone.0004384. Epub 2009 Feb 6. Erratum in: PLoS ONE. 2009;4(3). doi: 10.1371/annotation/5f2ae0fb-53f1-48c2-aa19-9114765ba029. Capecchi, Pamela [corrected to Capecchi, Pier Leopoldo].

6.

Immunogenicity and safety of a combination of two serogroup B meningococcal outer membrane vesicle vaccines.

Sandbu S, Feiring B, Oster P, Helland OS, Bakke HS, Naess LM, Aase A, Aaberge IS, Kristoffersen AC, Rydland KM, Tilman S, Nøkleby H, Rosenqvist E.

Clin Vaccine Immunol. 2007 Sep;14(9):1062-9. Epub 2007 Jul 18.

7.

New zealand epidemic strain meningococcal B outer membrane vesicle vaccine in children aged 16-24 months.

Wong S, Lennon D, Jackson C, Stewart J, Reid S, Crengle S, Tilman S, Aaberge I, O'Hallahan J, Oster P, Mulholland K, Martin D.

Pediatr Infect Dis J. 2007 Apr;26(4):345-50.

PMID:
17414400
8.

Aestiva ventilation mode selector switch failures.

Gravenstein D, Wilkhu H, Liem EB, Tilman S, Lampotang S.

Anesth Analg. 2007 Apr;104(4):860-2.

PMID:
17377096
9.

Immunogenicity and safety of a strain-specific MenB OMV vaccine delivered to under 5-year olds in New Zealand.

Oster P, O'Hallahan J, Aaberge I, Tilman S, Ypma E, Martin D.

Vaccine. 2007 Apr 20;25(16):3075-9. Epub 2007 Jan 22.

PMID:
17289223
10.

Safety review: two outer membrane vesicle (OMV) vaccines against systemic Neisseria meningitidis serogroup B disease.

Nøkleby H, Aavitsland P, O'Hallahan J, Feiring B, Tilman S, Oster P.

Vaccine. 2007 Apr 20;25(16):3080-4. Epub 2007 Jan 22.

PMID:
17287053
11.

Persisting immune responses indicating long-term protection after booster dose with meningococcal group B outer membrane vesicle vaccine.

Feiring B, Fuglesang J, Oster P, Naess LM, Helland OS, Tilman S, Rosenqvist E, Bergsaker MA, Nøkleby H, Aaberge IS.

Clin Vaccine Immunol. 2006 Jul;13(7):790-6.

12.

Safety and immunogenicity of New Zealand strain meningococcal serogroup B OMV vaccine in healthy adults: beginning of epidemic control.

Thornton V, Lennon D, Rasanathan K, O'Hallahan J, Oster P, Stewart J, Tilman S, Aaberge I, Feiring B, Nokleby H, Rosenqvist E, White K, Reid S, Mulholland K, Wakefield MJ, Martin D.

Vaccine. 2006 Feb 27;24(9):1395-400. Epub 2005 Oct 4.

PMID:
16242221

Supplemental Content

Loading ...
Support Center